Dicerna Pharmaceuticals (DRNA) Drops 10.38% on December 22

Equities Staff |

Dicerna Pharmaceuticals (DRNA) was one of the Russell 2000's biggest losers for Tuesday December 22 as the stock slid 10.38% to $12.78, a loss of $-1.48 per share. Starting at an opening price of $14.32 a share, the stock traded between $12.76 and $14.32 over the course of the trading day. Volume was 97,953 shares over 871 trades, against an average daily volume of 141,528 shares and a total float of 20.59 million.

The losses send Dicerna Pharmaceuticals down to a market cap of $263.18 million. In the last year, Dicerna Pharmaceuticals has traded between $27.33 and $7.61, and its 50-day SMA is currently $11.73 and 200-day SMA is $14.70.

Dicerna Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Dicerna Pharmaceuticals is based out of Cambridge, MA and has some 42 employees. Its CEO is Douglas M. Fambrough.

For a complete fundamental analysis analysis of Dicerna Pharmaceuticals, check out Equities.com’s Stock Valuation Analysis report for DRNA. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Veritas Pharma Inc.

Veritas Pharma Inc, formerly Seashore Organic Medicine Inc is an emerging producer and distributor of medical marijuana.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

Knightscope

Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.